Urate-lowering therapy in maintenance hemodialysis: focusing on gout burden rather than serum urate alone

Abstract Background Whether asymptomatic hyperuricemia should trigger pharmacologic intervention in maintenance hemodialysis remains unresolved. This question differs fundamentally from hyperuricemia management in the general population or in nondialysis chronic kidney disease because hemodialysis itself substantially alters urate kinetics, lowers serum urate during each session, and may contract the effective urate burden. In routine dialysis practice, predialysis serum urate values are frequently available and may prompt therapeutic uncertainty even when gout symptoms are absent. We reviewed the recent literature to clarify whether serum urate alone should prompt urate-lowering therapy in hemodialysis patients and to identify which patients may require individualized reassessment because of persistent gout burden. Main body Current evidence does not support a dialysis-specific serum urate threshold that justifies routine pharmacologic treatment of asymptomatic hyperuricemia. Hemodialysis markedly reduces circulating urate, and emerging work suggests that urate burden in hemodialysis may be better interpreted in the context of urate pool and extra-renal urate handling rather than serum urate concentration alone. In parallel, observational studies in hemodialysis have repeatedly shown that lower as well as higher serum urate levels are associated with worse survival, with low urate often linked to malnutrition, frailty, and inflammatory burden. These observations do not prove that low urate itself is harmful, but they caution against assuming that pharmacologic urate lowering is automatically beneficial in patients undergoing hemodialysis. Although cohort studies suggest possible associations between xanthine oxidoreductase inhibitor use and improved mortality or cardiovascular outcomes, these findings remain observational and do not establish a causal benefit in asymptomatic patients. Furthermore, urate-lowering therapy is not harmless: treatment initiation can precipitate gout flares, and flare prophylaxis is particularly challenging in dialysis because colchicine requires conservative use and close toxicity monitoring in severe kidney failure, particularly in the setting of interacting drugs. Drug-specific risks also remain relevant for allopurinol and febuxostat. Conclusions In maintenance hemodialysis, asymptomatic hyperuricemia should not automatically trigger pharmacologic intervention. In the absence of persistent gout burden, a cautious approach is more appropriate than routine serum urate-driven treatment. Treatment decisions should therefore be guided by persistent gout burden rather than by serum urate elevation alone.